

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Symmetry Medical Inc.
Form 10-Q
November 07, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2013

Commission File Number: 001-32374

SYMMETRY MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

35-1996126
(I.R.S. Employer Identification No.)

3724 North State Road 15, Warsaw, Indiana
(Address of principal executive offices)

46582
(Zip Code)

(574) 268-2252
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 Yes No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Accelerated filer
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

The number of shares outstanding of the registrant's common stock as of November 6, 2013 was 37,252,878 shares.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

| | | |
|---------------------------|--|-----------|
| Item 1 | Financial Statements: | <u>2</u> |
| | Condensed Consolidated Balance Sheets: As of September 28, 2013 and December 29, 2012 | <u>2</u> |
| | Condensed Consolidated Statements of Operations: Three and Nine Months Ended September 28, 2013 and September 29, 2012 | <u>3</u> |
| | Condensed Consolidated Statements of Comprehensive Income: Three and Nine Months Ended September 28, 2013 and September 29, 2012 | <u>4</u> |
| | Condensed Consolidated Statements of Cash Flows: Nine Months Ended September 28, 2013 and September 29, 2012 | <u>5</u> |
| | Notes to Condensed Consolidated Financial Statements | <u>6</u> |
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>19</u> |
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | <u>29</u> |
| Item 4 | Controls and Procedures | <u>29</u> |
| PART II OTHER INFORMATION | | |
| Item 1A | Risk Factors | <u>30</u> |
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | <u>30</u> |
| Item 6 | Exhibits | <u>30</u> |
| | Signatures | <u>31</u> |

Cautionary Note Regarding Forward-Looking Statements

Throughout this Quarterly Report on Form 10-Q or in other reports or registration statements filed from time to time with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, or under the Securities Act of 1933, as well as in documents we incorporate by reference or in press releases or oral statements made by our officers or representative, we may make statements that express our opinions, expectations or projections regarding future events or future results, in contrast with statements that reflect historical facts. These predictive statements, which we generally precede or accompany by such typical conditional words such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “potential,” or “expect,” or by the words “may,” “will,” “could,” or “should,” expressions or terminology are intended to operate as “forward-looking statements” of the kind permitted by the Private Securities Litigation Reform Act of 1995. That legislation protects such predictive statements by creating a “safe harbor” from liability in the event that a particular prediction does not turn out as anticipated.

Forward-looking statements convey our current expectations or forecast future events. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many uncertainties and other variable circumstances, many of which are outside of our control, that could cause our actual results and experience to differ materially from those we thought would occur.

We also refer you to and believe that you should carefully read the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” portions of our Annual Report for fiscal 2012 on Form 10-K, as well as in other reports which we file with the Securities and Exchange Commission, to better understand the risks and uncertainties that are inherent in our business and in owning our securities. These reports are available publicly on the SEC website, www.sec.gov, and on our website, www.symmetrymedical.com.

Any forward-looking statements which we make in this report or in any of the documents that are incorporated by reference herein speak only as of the date of such statement, and we undertake no ongoing obligation to update such statements. Comparisons of results between current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

PART I FINANCIAL INFORMATION

ITEM I. FINANCIAL STATEMENTS

SYMMETRY MEDICAL INC.
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (In Thousands)

| | September 28, 2013 (unaudited) | December 29, 2012 |
|--|--------------------------------------|----------------------|
| ASSETS: | | |
| Current Assets: | | |
| Cash and cash equivalents | \$4,897 | \$9,815 |
| Accounts receivable, net | 57,709 | 62,593 |
| Inventories | 60,574 | 64,437 |
| Refundable income taxes | 5,060 | 4,904 |
| Deferred income taxes | 6,409 | 7,878 |
| Derivative valuation asset | — | 242 |
| Other current assets | 4,069 | 4,145 |
| Total current assets | 138,718 | 154,014 |
| Property and equipment, net | 91,256 | 98,046 |
| Deferred income taxes | 43 | — |
| Goodwill | 181,873 | 229,134 |
| Intangible assets, net of accumulated amortization | 107,175 | 116,403 |
| Other assets | 6,005 | 7,721 |
| Total Assets | \$525,070 | \$605,318 |
| LIABILITIES AND SHAREHOLDERS' EQUITY: | | |
| Current Liabilities: | | |
| Accounts payable | \$26,882 | \$27,863 |
| Accrued wages and benefits | 11,159 | 9,354 |
| Other accrued expenses | 9,109 | 10,028 |
| Accrued income taxes | 516 | — |
| Derivative valuation liability | 271 | 513 |
| Current portion of capital lease obligations | 476 | 492 |
| Current portion of long-term debt | 5,225 | 11,111 |
| Total current liabilities | 53,638 | 59,361 |
| Accrued income taxes | 2,118 | 7,035 |
| Deferred income taxes | 5,887 | 17,910 |
| Derivative valuation liability | 1,661 | 3,883 |
| Other liabilities | 943 | 869 |
| Capital lease obligations, less current portion | 1,073 | 1,417 |
| Long-term debt, less current portion | 175,071 | 200,113 |
| Total Liabilities | 240,391 | 290,588 |
| Commitments and contingencies | | |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Shareholders' Equity:

| | | |
|--|-----------|-----------|
| Common Stock, \$.0001 par value; 75,000 shares authorized; shares issued September 28, 2013-37,253; December 29, 2012-36,795 | 4 | 4 |
| Additional paid-in capital | 288,986 | 287,453 |
| Retained earnings (deficit) | (7,374 |) 26,267 |
| Accumulated other comprehensive income | 3,063 | 1,006 |
| Total Shareholders' Equity | 284,679 | 314,730 |
| Total Liabilities and Shareholders' Equity | \$525,070 | \$605,318 |

See accompanying notes to condensed consolidated financial statements.

2

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except per Share Data; Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|--|-----------------------|-----------------------|-----------------------|-----------------------|
| | September 28, 2013 | September 29, 2012 | September 28, 2013 | September 29, 2012 |
| Revenue | \$98,003 | \$100,929 | \$298,815 | \$303,949 |
| Cost of revenue | 73,474 | 72,703 | 222,571 | 223,808 |
| Gross profit | 24,529 | 28,226 | 76,244 | 80,141 |
| Research and development expenses | 1,121 | 1,293 | 3,459 | 2,998 |
| Sales and marketing expenses | 6,516 | 6,107 | 20,451 | 19,868 |
| General and administrative expenses | 11,250 | 10,730 | 35,154 | 32,331 |
| Asset impairment | 51,646 | — | 51,646 | — |
| Facility closure and severance | 508 | (76 |) 1,431 | 596 |
| Operating income (loss) | (46,512 |) 10,172 | (35,897 |) 24,348 |
| Other (income) expense: | | | | |
| Interest expense | 4,337 | 4,737 | 13,508 | 14,905 |
| Derivatives valuation (gain) loss | 5 | (116 |) 242 | (179 |
| Other | 831 | (108 |) 933 | (562 |
| Income (loss) before income taxes | (51,685 |) 5,659 | (50,580 |) 10,184 |
| Income tax expense (benefit) | (17,161 |) 1,921 | (16,939 |) 3,980 |
| Net income (loss) | \$(34,524 |) \$3,738 | \$(33,641 |) \$6,204 |
| Net income (loss) per share: | | | | |
| Basic | \$(0.95 |) \$0.10 | \$(0.93 |) \$0.17 |
| Diluted | \$(0.95 |) \$0.10 | \$(0.93 |) \$0.17 |
| Weighted average common shares and equivalent shares outstanding: | | | | |
| Basic | 36,345 | 36,044 | 36,312 | 35,951 |
| Diluted | 36,345 | 36,512 | 36,312 | 36,360 |

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In Thousands; Unaudited)

| | Three Months Ended | | Nine Months Ended | | |
|--|-----------------------|-----------------------|-----------------------|-----------------------|---|
| | September 28, 2013 | September 29, 2012 | September 28, 2013 | September 29, 2012 | |
| Net income (loss) | \$(34,524 |) \$3,738 | \$(33,641 |) \$6,204 | |
| Foreign currency adjustments: | | | | | |
| Intra-entity foreign currency transaction adjustment | 1,333 | 858 | (33 |) 1,130 | |
| Foreign currency translation adjustments | 2,310 | 1,509 | 657 | 669 | |
| Net unrealized gains on derivative instruments: | | | | | |
| Unrealized holding gains (losses), net of taxes | (109 |) (480 |) 1,581 | (2,634 |) |
| Reclassification adjustment for realized (gains) losses included in net income | 47 | (46 |) 148 | (46 |) |
| Comprehensive income (loss) | \$(30,943 |) \$5,579 | \$(31,288 |) \$5,323 | |

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(In Thousands; Unaudited)

| | Nine Months Ended | |
|---|-----------------------|-----------------------|
| | September 28, 2013 | September 29, 2012 |
| Operating activities | | |
| Net income (loss) | \$(33,641 |) \$6,204 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation | 12,476 | 12,869 |
| Amortization of intangible assets | 5,343 | 6,037 |
| Amortization of debt issuance costs | 1,569 | 1,289 |
| Interest paid in kind | 1,006 | 1,002 |
| Net (gain) loss on sale of assets | 675 | (96 |
| Asset impairment | 51,646 | — |
| Deferred income tax provision | (16,522 |) 507 |
| Excess tax benefit from stock-based compensation | (57 |) (294 |
| Stock-based compensation | 1,934 | 3,076 |
| Derivative valuation (gain) loss | 242 | (179 |
| Foreign currency transaction (gain) loss | 1,391 | (173 |
| Change in operating assets and liabilities: | | |
| Accounts receivable | 5,005 | (720 |
| Other assets | 245 | 583 |
| Inventories | 3,853 | 12,663 |
| Current income taxes | 370 | 762 |
| Accounts payable | (1,036 |) 2,518 |
| Accrued expenses and other | (110 |) 5,912 |
| Net cash provided by operating activities | 34,389 | 51,960 |
| Investing activities | | |
| Purchases of property and equipment | (7,786 |) (9,128 |
| Proceeds from the sale of property and equipment | 655 | 319 |
| Net cash used in investing activities | (7,131 |) (8,809 |
| Financing activities | | |
| Proceeds from Bank Revolver | 82,687 | 21,839 |
| Payments on Bank Revolver | (85,687 |) (62,712 |
| Proceeds from (payments on) short term borrowings, net | — | (5,844 |
| Payments on bank term loans and capital lease obligations | (29,328 |) (3,490 |
| Proceeds from the issuance of common stock, net | (458 |) 178 |
| Excess tax benefit from stock-based compensation | 57 | 294 |
| Net cash used in financing activities | (32,729 |) (49,735 |
| Effect of exchange rate changes on cash | 553 | 19 |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| | | | |
|--|----------|-----------|---|
| Net decrease in cash and cash equivalents | (4,918 |) (6,565 |) |
| Cash and cash equivalents at beginning of period | 9,815 | 18,931 | |
| Cash and cash equivalents at end of period | \$4,897 | \$12,366 | |
| Supplemental disclosures: | | | |
| Cash paid for interest | \$11,381 | \$11,904 | |
| Cash paid (received) for income taxes | \$(966 |) \$2,363 | |
| See accompanying notes to condensed consolidated financial statements. | | | |

5

SYMMETRY MEDICAL INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In Thousands, Except Per Share Data; Unaudited)

1. Basis of Presentation

The condensed consolidated financial statements include the accounts of Symmetry Medical Inc. and its wholly-owned subsidiaries (collectively referred to as the Corporation), which operates in two reportable segments: (1) Original Equipment Manufacturer (“OEM”) Solutions and (2) Symmetry Surgical. The Corporation is a global supplier of integrated products consisting primarily of surgical implants, instruments and cases to orthopedic and other medical device companies. OEM Solutions primarily designs, develops and manufactures implants and related surgical instruments and cases for orthopedic device markets. Symmetry Surgical is the Corporation’s hospital direct business which sells a broad range of reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products, and sterilization containers.

The condensed consolidated financial statements of the Corporation have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments of a normal recurring nature considered necessary to present fairly the consolidated financial position of the Corporation, its results of operations and cash flows. The Corporation’s results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the fiscal year 2012 consolidated financial statements and the notes thereto included in the Corporation’s Annual Report on Form 10-K for fiscal year 2012.

The Corporation’s fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2013 is a 52 week year ending December 28, 2013. The Corporation’s interim quarters for 2013 are 13 weeks long and quarter-end dates have been set as March 30, 2013, June 29, 2013 and September 28, 2013. Fiscal year 2012 was a 52 week year (ending December 29, 2012). The Corporation’s interim quarters for 2012 were 13 weeks long, ending March 31, 2012, June 30, 2012 and September 29, 2012. References in these condensed consolidated financial statements to the three months ended refer to these financial periods, respectively.

2. New Accounting Pronouncements

Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income: In February 2013, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) 2013-2, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-2”). ASU 2013-2 requires entities to report either on the statement of operations or disclose in the footnotes to the consolidated financial statements the effects on earnings from items that are reclassified out of comprehensive income. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-2 is effective prospectively for the first reporting period after December 15, 2012 with early adoption permitted. The adoption of ASU 2013-2 did not have an impact on the Corporation’s consolidated financial position, results of operations or cash flows as it only enhances disclosures.

Technical Corrections and Improvements: In October 2012, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) 2012-4, Technical Corrections and Improvements (“ASU 2012-4”), which covers a wide range of topics in the Accounting Standards Codification. These amendments include technical

corrections and improvements to the Accounting Standards Codification and confirming amendments related to fair value measurements. ASU 2012-4 is effective for fiscal periods beginning after December 15, 2012. The adoption of ASU 2012-4 did not have an impact on the Corporation's consolidated financial position, results of operations or cash flows as the Standard only clarified existing Codification.

3. Inventories

Inventories consist of the following:

| | September 28, 2013 (unaudited) | December 29, 2012 |
|---------------------------|--------------------------------------|----------------------|
| Raw material and supplies | \$11,691 | \$12,683 |
| Work-in-process | 20,315 | 20,335 |
| Finished goods | 28,568 | 31,419 |
| | \$60,574 | \$64,437 |

4. Property and Equipment

Property and equipment, including depreciable lives, consists of the following:

| | September 28, 2013 (unaudited) | December 29, 2012 |
|---|--------------------------------------|----------------------|
| Land | \$5,969 | \$6,572 |
| Buildings and improvements (20 to 40 years) | 42,318 | 42,885 |
| Machinery and equipment (5 to 15 years) | 161,382 | 156,157 |
| Office equipment (3 to 5 years) | 21,367 | 19,445 |
| Construction-in-progress | 2,813 | 6,414 |
| | 233,849 | 231,473 |
| Less accumulated depreciation | (142,593 |) (133,427) |
| | \$91,256 | \$98,046 |

5. Goodwill and Other Intangible Assets

The Corporation has multiple operating segments which are comprised of multiple components that represent the lowest level for which discrete financial information is available and the operating results of that component are regularly reviewed by management. The Corporation aggregates certain components that share similar economic similarities and that are vertically integrated within the same operating segment into reporting units

In the third quarter, the Corporation determined that the expected operating results for certain of its reporting units were projected to be substantially lower than previous forecasts. Given this information, the Corporation conducted its annual impairment test and determined that impairment existed for three reporting units. The preliminary impairment is \$51,646 for goodwill and other assets and has been recorded in the condensed consolidated statements of operations within Asset Impairment. The Corporation recorded a pre-tax non-cash charge during the third quarter in the amount of \$31,837 related to the OEM Solutions segment and \$19,809 million related to the Symmetry Surgical segment. The impairment in OEM Solutions consisted of goodwill, trade names, customer relationships, and property and equipment of \$29,200, \$953, \$1,403, and \$281, respectively, and was primarily driven by the reduced outlook on revenues and profitability related to instrument production for customer capital expenditures related to product launches and instrument replenishment, as well as operational issues at the Clamonta, Ltd. subsidiary, which services the Aerospace industry. The impairment in Symmetry Surgical consisted of goodwill, tradenames and in-process

research and development of \$18,278, \$921, and \$610, respectively, and was primarily driven by lower revenue due to the previously disclosed integration challenges related to the 2011 acquisition of the surgical instruments business of Codman & Shurtleff, Inc. ("Codman") which the Corporation has not recovered from as quickly as previously expected.

7

The Corporation will finalize the estimated impairment charge during the fourth quarter of fiscal year 2013. The Corporation is in process of finalizing the appraisals of its reporting units, intangible assets, property, plant and equipment and other assets and liabilities.

The Corporation determines the fair value of intangible assets using an income based approach. The approach calculates fair value by estimating the after-tax cash flows attributable to the asset and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. The calculated fair value is compared to the carrying value to determine if any impairment exists.

To derive the fair value of the reporting units, as required in step one of the impairment test, the Corporation used the income approach, specifically the discounted cash flow method, to determine the fair value of each reporting units and the associated amount of the impairment charges. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. This methodology is consistent with how the Corporation estimates the fair value of its reporting units during its annual goodwill and indefinite lived intangible asset impairment tests. Inputs used to fair value the Corporation's reporting units are considered Level 3 inputs of the fair value hierarchy and include the following:

The Corporation's financial projections for its reporting units are based on management's assessment of macroeconomic variables, industry trends and market opportunities, as well as the Corporation's strategic objectives and future growth plans. Revenue growth rates assumed for each of the Corporation's reporting units where impairment was recognized were approximately 4-34% for 2014 and 2-8% for 2015 and beyond.

The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data, as well as the Corporation's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Corporation's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise. Discount rates used for each of the Corporation's reporting units where impairment was recognized were approximately 12.5%, 15.8% and 12.5%.

For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement.

In the second step, the Corporation assigned the reporting unit's fair value to all of its assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the reporting unit were being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment charge. This allocation process was performed only for the purposes of measuring the goodwill impairment and not to adjust the carrying values of the recognized assets and liabilities. Based on the results of this testing, the Corporation's OEM Solutions reporting segment impaired goodwill for \$29,200, while the Corporation's Symmetry Surgical reporting segment impaired goodwill for \$18,278.

Prior to performing the annual goodwill impairment tests for the reporting units whom failed step 1, the Corporation tested long-lived assets to be held and used for impairment on an undiscounted cash flow basis. Based on the results of this testing, the Corporation's OEM Solutions reporting segment impaired trade names, customer relationships, and property and equipment of \$953, \$1,403, and \$281, respectively, while the Corporation's Symmetry Surgical reporting segment impaired tradenames and in-process research and development of \$921, and \$610, respectively.

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

As of September 28, 2013, the balances of intangible assets, other than goodwill, were as follows:

| | Weighted-Average Amortization Period (unaudited) | Gross Intangible Assets (unaudited) | Accumulated Amortization (unaudited) | Net Intangible Assets (unaudited) |
|---|---|--|--|--|
| Acquired technology and patents | 11 years | \$1,730 | \$(1,143) |) \$587 |
| Acquired customers | 19 years | 123,946 | (26,074) |) 97,872 |
| Intangible assets subject to amortization | 19 years | 125,676 | (27,217) |) 98,459 |
| Proprietary processes | Indefinite | | | 3,577 |
| Trademarks | Indefinite | | | 5,139 |
| Indefinite-lived intangible assets, other than goodwill | | | | 8,716 |
| Total | | | | \$107,175 |

As of December 29, 2012, the balances of intangible assets, other than goodwill, were as follows:

| | Weighted-Average Amortization Period | Gross Intangible Assets | Accumulated Amortization | Net Intangible Assets |
|---|--|-------------------------------|-----------------------------|-----------------------------|
| Acquired technology and patents | 12 years | \$2,161 | \$(1,467) |) \$694 |
| Acquired customers | 19 years | 126,481 | (22,027) |) 104,454 |
| Other | 17 years | 1,421 | (414) |) 1,007 |
| Intangible assets subject to amortization | 19 years | 130,063 | (23,908) |) 106,155 |
| Proprietary processes | Indefinite | | | 3,578 |
| In process research and development | Indefinite | | | 610 |
| Trademarks | Indefinite | | | 6,060 |
| Indefinite-lived intangible assets, other than goodwill | | | | 10,248 |
| Total | | | | \$116,403 |

Annual intangible asset amortization expense is estimated to approximate \$6,900 for each of the next 5 fiscal years.

The reconciliation of the beginning and ending carrying amounts of goodwill are as follows:

| | |
|----------------------------------|-----------|
| Balance as of December 31, 2011 | \$229,112 |
| Adjustment to goodwill | (402) |
| Effects of foreign currency | 424 |
| Balance as of December 29, 2012 | \$229,134 |
| Impairment of goodwill | (47,479) |
| Effects of foreign currency | 218 |
| Balance as of September 28, 2013 | \$181,873 |

6. Derivatives

The Corporation utilizes derivative instruments to minimize the volatility of cash flows and statement of operations impacts associated with interest rate payments on its variable rate debt and the impact of fluctuations in foreign currency. The Corporation recognizes all derivative instruments as either assets or liabilities at fair value on the consolidated balance sheets. Derivative asset and liability amounts with the same counterparty are netted against each

other for financial reporting purposes. The Corporation utilizes third party valuations to assist in the determination of the fair value of these derivatives. The Corporation considered its derivative instrument valuations to be Level 2 fair value measurements.

To the extent a derivative instrument was designated effective as a cash flow hedge of an exposure to changes in the fair value of a future transaction, the change in fair value of the derivative was deferred in accumulated other comprehensive income, a component of shareholders' equity in the consolidated balance sheets, until the underlying transaction hedged was recognized in the consolidated statements of operations. The Corporation accounts for certain derivatives hedging the payment of interest as cash flow hedges and the impact of the hedge was reclassified to interest expense in the consolidated statements of operations upon payment of interest.

The Corporation's profitability and cash flows are affected by changes in interest rates, specifically LIBOR. The primary purpose of the Corporation's interest rate risk management activities is to hedge its exposure to changes in interest rates. The Corporation's Amended Credit Agreement requires that the interest be hedged on at least 50% of the current and projected borrowings under the Amended Credit Agreement for a period of at least 3 years beginning no later than March 29, 2012. In March, 2012, the Corporation entered into two forward swap contracts to manage interest rate risk related to its Bank Term Loan and a portion of its Bank Revolver. The notional amount on the swap contracts is \$79,494 as of September 28, 2013 and is reduced to \$37,500 by December 2022 in line with expected reductions in the related debt instruments. The fixed per annum interest rate on the swap contracts is 0.60% in 2013 that incrementally increase to 3.81% by 2022. These swap contracts, which were a fair value liability of \$1,932 and \$4,396 as of September 28, 2013 and December 29, 2012, respectively, were designated as cash flow hedges of the future payments of variable rate interest with one-month LIBOR. For the three and nine months ended September 28, 2013, the Corporation recorded gain/(loss) of (\$264) and \$2,464, respectively, attributable to these cash flow hedges included in other comprehensive income. Of the total cumulative loss, \$271 will be reclassified into earnings in the next twelve months.

In June and July 2012, the Corporation entered into forward swap contracts to mitigate the impact of fluctuations in foreign currency on the statement of operations. As of September 28, 2013, the Corporation had settled all of its outstanding forward swap contracts. As of December 29, 2012, the Corporation had contracts for the sale of 3,161 Euros, which were settling in equal amounts over the twelve month period which began July 2012. These swap contracts, which were an aggregate fair value asset of \$242 at December 29, 2012, were not designated as cash flow hedges and therefore the change in the fair value was immediately recorded in derivatives valuation (gain) loss in the consolidated statements of operations.

7. Fair Value of Financial Instruments

As of September 28, 2013, the Corporation held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These included the Corporation's cash equivalents and derivative instruments in the form of interest rate swaps and foreign currency forward contracts. The Corporation's cash equivalents include highly liquid financial instruments that are readily convertible with maturities of 90 days or less. The Corporation's derivative instruments consist of contracts that are not traded on a public exchange. The fair values of interest rate derivative instruments and foreign currency forward contracts are determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets. Therefore, the Corporation has categorized these derivative instruments as Level 2 in accordance with the FASB Standard on fair value measurement.

On a recurring basis management measures the fair value of its interest rate swaps using the market approach based on projections of the one month LIBOR rate over the life of each swap. Also on a recurring basis, management measures the fair value of its foreign currency forward contracts using the market approach based on the projections of the Euro rate over the life of each forward contract. The fair value and carrying value of the Corporation's assets and liabilities measured at fair value on a recurring basis were as follows:

September 28, 2013

December 29, 2012

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| | Fair Value Measurements | | | | Fair Value Measurements | | | |
|---------------------------|-------------------------|-----------|---------|-----------|-------------------------|-----------|---------|-----------|
| | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total |
| | (unaudited) | | | | | | | |
| Assets | | | | | | | | |
| Cash equivalents | \$— | \$570 | \$— | \$570 | \$— | \$920 | \$— | \$920 |
| Foreign currency forwards | — | — | — | — | — | 242 | — | 242 |
| Total assets | \$— | \$570 | \$— | \$570 | \$— | \$1,162 | \$— | \$1,162 |
| Liabilities | | | | | | | | |
| Interest rate swaps | \$— | \$(1,932) | \$— | \$(1,932) | \$— | \$(4,396) | \$— | \$(4,396) |
| Total liabilities | \$— | \$(1,932) | \$— | \$(1,932) | \$— | \$(4,396) | \$— | \$(4,396) |

10

Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis and are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment. Assets and liabilities acquired in business combinations are recorded at their fair value as of the date of acquisition.

The Corporation is in the process of performing its annual impairment test for goodwill. The fair value of the reporting units is determined using the income approach. The income approach focuses on the income-producing capability of an asset, measuring the current value of the asset by calculating the present value of its future economic benefits such as cash earnings, cost savings, corporate tax structure and product offerings. Value indications are developed by discounting expected cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation and risks associated with the reporting unit. These assets are classified within Level 3, in the event that the Corporation were required to measure and record such assets at fair value within its consolidated financial statements, as discussed in the Note 5, Goodwill and Other Intangible Assets.

The Corporation periodically evaluates the carrying value of long-lived assets to be held and used, including definite-lived intangible assets and property plant and equipment, when events or circumstances warrant such a review. Fair value is determined primarily using anticipated cash flows assumed by a market participant, discounted at a rate commensurate with the risk involved and these assets would generally be classified within Level 3, in the event that the Corporation were required to measure and record such assets at fair value within its consolidated financial statements.

Additionally, financial instruments also consist of cash, accounts receivable, accounts payable and long-term debt. The carrying value of long-term debt materially approximates fair value. Additionally, the fair value of cash and net accounts receivables and payables was estimated by management to approximate fair value due to the relatively short period of time to maturity for these instruments.

8. Debt Arrangements

The Corporation's Amended Credit Agreement currently provides for a \$200,000 revolving line of credit (Bank Revolver) and a \$50,000 bank term loan (Bank Term Loan). The Amended Credit Agreement also includes an accordion feature, which permits the Corporation to borrow up to an additional \$50,000 in the form of additional term loans or an increase in the Bank Revolver subject to the terms and conditions set forth in the Amended Credit Agreement. The Amended Credit Agreement, which is senior and secured, has an aggregate of \$113,288 outstanding as of September 28, 2013.

Borrowings under the Amended Credit Agreement bear interest at a rate per annum based upon LIBOR, the Federal Funds rate or the Lenders' prime rate, in each case plus an applicable margin, at the Corporation's option. The Bank Term Loan is to be repaid in quarterly installments of \$2,778, may be prepaid, in whole or in part, at the option of the Corporation, and is required to be prepaid using all or a portion of the net cash proceeds of certain asset sales, recovery events, and issuances of new debt or equity and, depending on the Corporation's Total Leverage Ratio (as defined in the Amended Credit Agreement), using a portion of the Corporation's Excess Cash Flow (as defined in the Amended Credit Agreement) (the "Excess Cash Flow Prepayment"). The Excess Cash Flow Prepayment is required to be made within 90 days of the end of the fiscal year in which the Excess Cash Flow is generated. The Bank Revolver matures on November 3, 2015 and the Bank Term Loan matures on December 31, 2016.

The Amended Credit Agreement contains various financial covenants, including covenants imposing a maximum ratio of total debt to EBITDA (as defined in the Amended Credit Agreement) and prescribing a minimum ratio of EBITDA to fixed charges (as defined in the Amended Credit Agreement). The Amended Credit Agreement also

contains covenants restricting certain corporate actions, including asset dispositions, acquisitions, payment of dividends and certain other restricted payments, changes of control, incurring indebtedness, incurring liens, making loans and investments and transactions with affiliates. The Amended Credit Agreement is secured by substantially all of the assets of the Corporation (and its U.S. subsidiaries) and also contains customary events of default.

The Corporation currently has \$67,008 of Term Notes outstanding that mature on December 29, 2017. The outstanding principal balance of the Term Notes bears interest at a rate of 14% per annum. The Term Notes include customary representations, warranties and covenants made for the benefit of the parties to the agreement. The covenants include, but are not limited to, requirements to provide financial information and notice of other events to the lenders, as well as restrictions on the incurrence of indebtedness, the creation or existence of liens, sales of assets, transactions with affiliates and other matters. The Term Notes also include financial covenants, including covenants requirement a maximum ratio of total debt to EBITDA (as defined in the Term Notes Agreement) and ratio of minimum fixed charges to EBITDA. The agreement includes customary

events of default, including but not limited to, failure to pay any principal, interest, fees or other amounts when due, default under any covenant or any agreement in any loan document (subject to cure periods in some cases), cross-default with other debt agreements and certain bankruptcy and insolvency events. While not secured by the Corporation's assets, repayment of amounts outstanding under the Term Notes is guaranteed by all of the Corporation's U.S. subsidiaries.

As of September 28, 2013, the most restrictive financial covenants per the Corporation's lending arrangements included the debt to EBITDA covenant ratio to be less than 3.50:1. The Corporation's ratio was approximately 3.20:1. The minimum interest coverage ratio is required to be greater than 1.20:1, and the Corporation's ratio at September 28, 2013 was approximately 1.84:1. As of December 28, 2013, these financial covenants will become more restrictive and then remain in effect until maturity. The debt to EBITDA covenant ratio will be required to be less than 3.25:1, and the minimum interest coverage ratio will be required to be greater than 1.25:1.

In May 2013, the Corporation was notified by one of its lenders that payments made by the Corporation in the first quarter of 2013 had been applied to the Bank Revolver, rather than the Bank Term Loan to satisfy the Corporation's obligation to make the Excess Cash Flow Prepayment as required by the Amended Credit Agreement. The failure to timely make the Excess Cash Flow Prepayment was a default under the Amended Credit Agreement and Term Notes. The Corporation entered into a limited waiver with its lenders under the Amended Credit Agreement and with the holders of the Term Notes that waived the event of default resulting from the failure to timely make the Excess Cash Flow Prepayment, and the Corporation made the required \$22,073 Excess Cash Flow Prepayment with borrowings under the Corporation's Bank Revolver. Future quarterly payments due on the Bank Term Loan will be reduced by a proportionate amount as a result of the reduction in outstanding principal from the Excess Cash Flow prepayment.

After obtaining the waivers noted above, the Corporation was in compliance with all covenants as of September 28, 2013.

9. Other Comprehensive Income

Amounts reclassified from accumulated other comprehensive income (loss) to earnings during the three and nine months ended September 28, 2013 and September 29, 2012 were as follows:

| Details about accumulated other comprehensive income components | Amount reclassified from accumulated other comprehensive income | | | | Affected line item in the statement where net income is presented |
|---|---|--------------------|-----------------------------------|--------------------|---|
| | Three Months Ended | | Nine Months Ended | | |
| | September 28, 2013 (unaudited) | September 29, 2012 | September 28, 2013 (unaudited) | September 29, 2012 | |
| Realized (gains) losses on derivative instruments | \$84 | \$(71) | \$264 | \$(71) | Interest expense |
| Tax expense (benefit) | (37) |) 25 | (116) |) 25 | Income tax expense (benefit) |
| Net of tax | \$47 | \$(46) | \$148 | \$(46) | |

10. Income Taxes

The provision for income taxes differs from that computed at the Federal statutory rate of 35% in 2013 and 2012, respectively, as follows:

12

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------------------------|-----------------------|--------------------------------------|-----------------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | September 28, 2013 (unaudited) | September 29, 2012 |
| Tax at Federal statutory rate | \$ (18,090) | \$ 1,981 | \$ (17,703) | \$ 3,565 |
| State income taxes | (2,015) | 239 | (1,996) | 430 |
| State tax credits | (72) | (38) | (68) | (68) |
| Foreign income taxes | 869 | 30 | 811 | 54 |
| Qualified production activities deduction | 14 | (134) | — | (241) |
| Research and development credits--current year | (195) | (24) | (212) | (42) |
| Valuation allowance | 579 | (287) | 540 | 692 |
| Goodwill impairment | 6,581 | — | 6,581 | — |
| Reserve for uncertain tax positions | (4,970) | 62 | (4,914) | 111 |
| Other | 138 | 92 | 22 | (521) |
| | \$ (17,161) | \$ 1,921 | \$ (16,939) | \$ 3,980 |

The Corporation's policy with respect to interest and penalties associated with reserves for uncertain tax positions is to classify such interest and penalties in income tax expense in the statements of operations. As of September 28, 2013, the total amount of unrecognized income tax benefits computed under ASC 740 was approximately \$1,966, all of which, if recognized, would impact the effective income tax rate of the Corporation. As of September 28, 2013 and December 29, 2012, the Corporation had recorded a total of \$152 and \$856, respectively, in accrued interest and penalties related to uncertain tax positions. The Corporation does not foresee material changes in its reserves for uncertain income tax positions as reasonably possible during the next 12 months. During 2013, certain reserves relating to federal income tax positions expired due to the statutes of limitations. As such, the consolidated statement of operations was benefited \$5,231 through a reduction in income tax expense. As of September 28, 2013, the Corporation is subject to unexpired statutes of limitations for U.S. federal income taxes for the year 2009. The Corporation is also subject to unexpired statutes of limitations for various states including most significantly Indiana, Massachusetts and New Hampshire generally for the years 2009-2012.

The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

| | |
|--|----------|
| Balance at December 31, 2011 | \$6,179 |
| Additions based on tax positions--current year | — |
| Additions for tax positions--prior years | — |
| Settlements | — |
| Balance at December 29, 2012 | 6,179 |
| Additions based on tax positions--current year | 82 |
| Additions for tax positions--prior years | 936 |
| Settlements | — |
| Lapses of statutes of limitations | (5,231) |
| Balance at September 28, 2013 | \$1,966 |

11. Segment Reporting

The Corporation has two reportable segments: OEM Solutions and Symmetry Surgical. OEM Solutions primarily designs, develops and manufactures implants and related surgical instruments and cases for orthopedic device companies and companies in other medical device markets such as arthroscopy, dental, laparoscopy, osteobiologic and endoscopy. OEM Solutions also manufactures specialized non-healthcare products, primarily in the aerospace industry. OEM Solutions manages its business in multiple operating segments. Because of the similar economic characteristics of these operations, including the nature of the products, comparable level of FDA regulations, and

same or similar customers, those operations have been aggregated for segment reporting purposes. Symmetry Surgical is the Corporation's hospital direct business which sells a broad range of reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products (vein strippers, SECTO dissectors, tonsil sponges and surgical marker pens), and sterilization containers. These products are typically used in the surgical specialties of spine, general/OB-GYN, microsurgery/neurosurgery, orthopedics, laparoscopy, cardiovascular, thoracic and general surgery in the hospital setting as well as surgery centers and in select physician offices.

The Corporation is a multi-national company with operations in the U.S., United Kingdom, France, Ireland, Malaysia, Germany and Switzerland. As a result, the Corporation's financial results can be impacted by currency exchange rates in the

foreign markets in which the Corporation sells its products. Revenues are attributed to geographic locations based on the location to which we ship our products.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies in the Corporation's 2012 Form 10-K, except that the Corporation evaluates segment performance based on income from operations. The Corporation allocates certain administrative corporate charges to the OEM Solutions and Symmetry Surgical reportable segments. Other Corporation charges, such as interest, income taxes and remaining unallocated administrative charges have not been allocated to the OEM Solutions or Symmetry Surgical reportable segments. The Corporation generally accounts for intersegment sales and transfers at cost plus a specified mark-up.

Reportable segment information is as follows:

| | Three Months Ended September 28, 2013 | | | | | |
|----------------------------------|---------------------------------------|----------------------|-------------|----------------------|--------------|-----------------------|
| | OEM Solutions (unaudited) | Symmetry Surgical | Unallocated | Combined segments | Eliminations | Consolidated Total |
| Revenues | | | | | | |
| External revenues | \$75,785 | \$22,218 | — | \$98,003 | — | \$98,003 |
| Intersegment revenues | 1,575 | 13 | — | 1,588 | \$(1,588) | — |
| Total revenues | 77,360 | 22,231 | — | 99,591 | (1,588) | 98,003 |
| Depreciation and amortization | 4,358 | 1,523 | \$62 | 5,943 | — | 5,943 |
| Operating income (loss) | (25,708) | (18,290) | (2,558) | (46,556) | 44 | (46,512) |
| Interest expense | | | | | | 4,337 |
| Derivatives valuation loss | | | | | | 5 |
| Other | | | | | | 831 |
| Loss before income taxes | | | | | | (51,685) |
| Total assets | 324,850 | 183,420 | 16,800 | 525,070 | — | 525,070 |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| | Three Months Ended September 29, 2012 | | | | | |
|-------------------------------|---------------------------------------|-------------------|-------------|-------------------|--------------|--------------------|
| | OEM Solutions (unaudited) | Symmetry Surgical | Unallocated | Combined segments | Eliminations | Consolidated Total |
| Revenues | | | | | | |
| External revenues | \$76,132 | \$24,797 | — | \$100,929 | — | \$100,929 |
| Intersegment revenues | 2,703 | 74 | — | 2,777 | \$(2,777) | — |
| Total revenues | 78,835 | 24,871 | — | 103,706 | (2,777) | 100,929 |
| Depreciation and amortization | 4,488 | 1,642 | \$54 | 6,184 | — | 6,184 |
| Operating income (loss) | 9,394 | 4,298 | (3,328) | 10,364 | (192) | 10,172 |
| Interest expense | | | | | | 4,737 |
| Derivatives valuation gain | | | | | | (116) |
| Other | | | | | | (108) |
| Income before income taxes | | | | | | 5,659 |
| Total assets | 380,568 | 211,568 | 20,637 | 612,773 | — | 612,773 |
| | | | | | | |
| | Nine Months Ended September 28, 2013 | | | | | |
| | OEM Solutions (unaudited) | Symmetry Surgical | Unallocated | Combined segments | Eliminations | Consolidated Total |
| Revenues | | | | | | |
| External revenues | \$232,096 | \$66,719 | — | \$298,815 | — | \$298,815 |
| Intersegment revenues | 4,046 | 48 | — | 4,094 | \$(4,094) | — |
| Total revenues | 236,142 | 66,767 | — | 302,909 | (4,094) | 298,815 |
| Depreciation and amortization | 13,135 | 4,520 | \$164 | 17,819 | — | 17,819 |
| Operating income (loss) | (11,649) | (16,330) | (7,965) | (35,944) | 47 | (35,897) |
| Interest expense | | | | | | 13,508 |
| Derivatives valuation loss | | | | | | 242 |
| Other | | | | | | 933 |
| Loss before income taxes | | | | | | (50,580) |
| Total assets | 324,850 | 183,420 | 16,800 | 525,070 | — | 525,070 |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| | Nine Months Ended September 29, 2012 | | | | | |
|-------------------------------|--------------------------------------|-------------------|-------------|-------------------|--------------|--------------------|
| | OEM Solutions (unaudited) | Symmetry Surgical | Unallocated | Combined segments | Eliminations | Consolidated Total |
| Revenues | | | | | | |
| External revenues | \$225,178 | \$78,771 | — | \$303,949 | — | \$303,949 |
| Intersegment revenues | 6,854 | 292 | — | 7,146 | \$(7,146) | — |
| Total revenues | 232,032 | 79,063 | — | 311,095 | (7,146) | 303,949 |
| Depreciation and amortization | 13,895 | 4,850 | \$161 | 18,906 | — | 18,906 |
| Operating income (loss) | 18,047 | 15,085 | (8,679) | 24,453 | (105) | 24,348 |
| Interest expense | | | | | | 14,905 |
| Derivatives valuation gain | | | | | | (179) |
| Other | | | | | | (562) |
| Income before income taxes | | | | | | 10,184 |
| Total assets | 380,568 | 211,568 | 20,637 | 612,773 | — | 612,773 |

Revenues to External Customers:

| | Three Months Ended | | Nine Months Ended | |
|-------------------------|-----------------------------------|--------------------|-----------------------------------|--------------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | September 28, 2013 (unaudited) | September 29, 2012 |
| United States | \$73,464 | \$73,473 | \$223,478 | \$223,124 |
| Ireland | 5,140 | 5,432 | 17,475 | 16,455 |
| United Kingdom | 7,311 | 8,036 | 22,953 | 22,489 |
| Other foreign countries | 12,088 | 13,988 | 34,909 | 41,881 |
| Total revenues | \$98,003 | \$100,929 | \$298,815 | \$303,949 |

Concentration of Credit Risk:

A substantial portion of the Corporation's net revenues is derived from a limited number of customers. Net revenue from customers of the Corporation which individually account for 10% or more of the Corporation's net revenue is as follows:

Three months ended September 28, 2013- Two customers represented approximately 31.4% and 10.0%, respectively, of revenue.

Nine months ended September 28, 2013- One customer represented approximately 32.1% of revenue.

Three months ended September 29, 2012- One customer represented approximately 32.3% of revenue, however, excluding the Codman related transitional services agreement, this customer would represent 29.9%.

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Nine months ended September 29, 2012- One customer represented approximately 32.6% of revenue, however, excluding the Codman related transitional services agreement, this customer would represent 29.6%.

Following is a summary of the composition by segment and product category of the Corporation's net revenues to external customers.

16

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

| Sales by product | Three Months Ended | | Nine Months Ended | |
|---------------------------------|-----------------------------------|--------------------|-----------------------------------|--------------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | September 28, 2013 (unaudited) | September 29, 2012 |
| OEM Solutions Revenue | | | | |
| Instrument | \$27,200 | \$29,633 | \$83,445 | \$85,197 |
| Implant | 26,108 | 25,632 | 80,213 | 75,499 |
| Cases | 16,959 | 14,209 | 50,432 | 44,569 |
| Other | 5,518 | 6,658 | 18,006 | 19,913 |
| Total OEM Solutions Revenue | 75,785 | 76,132 | 232,096 | 225,178 |
| Total Symmetry Surgical Revenue | 22,218 | 24,797 | 66,719 | 78,771 |
| Total Revenue | \$98,003 | \$100,929 | \$298,815 | \$303,949 |

12. Net Income Per Share

The following table sets forth the computation of earnings per share.

| | Three Months Ended | | Nine Months Ended | |
|--|-----------------------------------|--------------------|-----------------------------------|--------------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | September 28, 2013 (unaudited) | September 29, 2012 |
| Earnings per share - Basic: | | | | |
| Net income (loss) | \$(34,524) |) \$3,738 | \$(33,641) |) \$6,204 |
| Weighted-average common shares outstanding - Basic | 36,345 | 36,044 | 36,312 | 35,951 |
| Earnings per share - Basic | \$(0.95) |) \$0.10 | \$(0.93) |) \$0.17 |
| Earnings per share - Diluted: | | | | |
| Net income (loss) | \$(34,524) |) \$3,738 | \$(33,641) |) \$6,204 |
| Weighted-average common shares outstanding - Basic | 36,345 | 36,044 | 36,312 | 35,951 |
| Effect of dilution | — | 468 | — | 409 |
| Weighted-average common shares outstanding - Diluted | 36,345 | 36,512 | 36,312 | 36,360 |
| Earnings per share - Diluted | \$(0.95) |) \$0.10 | \$(0.93) |) \$0.17 |

As of September 29, 2012, the diluted weighted average share calculations do not include performance based restricted stock awarded in 2012 totaling 273 shares due to the respective measurement period not being complete.

13. Accounts Receivable Factoring

In January 2012, the Corporation entered into an agreement with an unrelated third-party for the factoring of specific accounts receivable in the U.K. to reduce the amount of working capital required to fund such receivables. The factoring of accounts receivable under this agreement is accounted for as a sale in accordance with ASC 860, Transfers and Servicing. Proceeds on the transfer reflect the face value of the account less a discount. The discount is recorded as a charge in general and administrative expenses in the consolidated statement of operations in the period of the sale. Net funds received reduced accounts receivable outstanding while increasing cash. The Corporation has no significant retained interests, nor any continuing

involvement or servicing liabilities related to the accounts receivable that have been sold. For the three months ended September 28, 2013 and September 29, 2012, the Corporation had sold \$948 and \$1,644, respectively, and \$2,958 and \$5,299 for the nine months then ended, of accounts receivable pursuant to this agreement, which represents the face amount of total outstanding receivables at the time the receivables are sold. Fees paid pursuant to this agreement were \$6 and \$12 for the three months ended September 28, 2013 and September 29, 2012, respectively, and \$21 and \$37 for the nine months then ended.

14. Commitments and Contingencies

Legal & Environmental Matters. The Corporation is involved, from time to time, in various contractual, product liability, patent (or intellectual property) and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Corporation, threatened, that the Corporation expects to have a material adverse effect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Corporation currently believes that the disposition of all pending or, to the knowledge of the Corporation, threatened claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Corporation's consolidated financial condition, results of operations or liquidity.

Unconditional Purchase Obligations. The Corporation has contracts to purchase minimum quantities of cobalt chrome, nickel and titanium through July 2014. Based on contractual pricing at September 28, 2013, the minimum purchase obligations total \$6,734. Purchases under cobalt chrome, nickel and titanium contracts total approximately \$9,951 for the nine months ended September 28, 2013. These purchases are not in excess of our forecasted requirements.

15. Facility Closure and Severance Costs

Results of operations include pre-tax charges of \$508 and \$(76) for the three months ended September 28, 2013 and September 29, 2012, respectively, and \$1,431 and \$596 for the nine months then ended. As of September 28, 2013 and December 29, 2012, severance accruals related to these cost reduction actions totaled \$592 and \$177, respectively, and are included in other accrued expenses in the consolidated balance sheets. The increase in the accrual since December 29, 2012 represents severance charges incurred but not paid during the second and third quarters of 2013. These costs are expected to be paid through June 2014.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview

Symmetry Medical Inc. is a leading global source of medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. We employ over 2,500 teammates around the world who are dedicated to being the trusted global source of innovative medical device solutions and surgical instruments for today's needs and tomorrow's growth.

In our OEM Solutions segment, we offer our original equipment manufacturer (OEM) customers instruments, implants and sterilization cases and trays. Symmetry Surgical, our hospital direct medical distribution business is complementary to core competencies and is not competitive with our OEM customers. Our salespeople call on hospital personnel in the operating room, materials management and central sterile departments. Our goal is to offer best-in-class quality and regulatory systems as well as customer innovation through Total Solutions® collaborations.

During the third quarter 2013, Symmetry's OEM Solutions business revenue decreased \$347, or 0.5%, compared to the third quarter 2012. This decrease reflects lower instrument revenue from our customers' new product launches, operational output issues at the Corporation's Clamonta Ltd. subsidiary, which serves the aerospace industry, a fire at our Sheffield, U.K. facility resulting in delayed shipments, partially offset by increased capital spending by our customers on cases to support new product launches. During the third quarter 2013, our combined five largest OEM customers increased revenue by 4.1% compared to the third quarter 2012, primarily driven by an increase in their capital expenditures and increased new product launch volume. Our overall OEM Solutions revenue in the third quarter 2013 decreased by \$3,846 from the second quarter 2013 as strong implant revenue in the second quarter 2013 driven by the timing of stocking orders and inventory adjustments did not repeat as well as softer instrument customer demand, operational output issues at the Corporation's Clamonta Ltd. subsidiary, and the fire at our Sheffield, U.K. facility.

During the third quarter 2013, Symmetry Surgical revenue decreased \$2,579, or 10.4%, compared to the third quarter 2012. This decrease was primarily due to sales disruptions associated with transitions to distributorships in the rest of the world related to the integration of the Codman surgical instruments business as well as the transfer of regulatory authorizations from Johnson & Johnson to Symmetry Surgical. During third quarter, we launched a comprehensive Symmetry Surgical product catalog - highlighting the significant breadth of our product portfolio - to reinforce to customers the scope and breadth of our offerings and trained our sales force. We believe these actions have helped to stabilize the business, as evidenced by only a slight decrease in sales from the second quarter of 2013.

Outside of the U.S., Symmetry Surgical continues to work to increase business with both new and existing distributors. We have successfully transferred regulatory approvals for product labeled in legacy graphics in the vast majority of countries and are in the process of registering the new Symmetry Surgical labeling of these products in all countries as well. We are also engaged in a similar process for the former SSI and Olsen product lines, which previously had only been in very limited international distribution, so that we may offer these products to customers throughout the world. While this will take considerable time, and will likely not impact our international business during 2013, we believe that this action will create longer-term growth opportunities. We expect this investment and new international customer service center in Switzerland to help regain our momentum in international markets and improve overall performance.

We believe that the Symmetry Surgical business is operating in an environment with temporary impediments to market growth. The most significant of these was the trend of flat to negative general surgical procedure rates in the U.S. and Europe during 2013.

Overall, we believe our corrective actions are having a positive impact on the Symmetry Surgical business segment, although continuing initiatives are required to fully address the challenges identified above. We expect continued pressure in this business for the remainder of 2013 and will be looking closely at realizing cost efficiencies post integration to improve profitability.

The sluggish global economy, high unemployment rates and lower than historical levels of surgical implant procedure growth continued to adversely impact customer demand. We continue to be optimistic about the long-term future as the larger OEMs are increasingly focused on improving their supply chains. We believe this will result in fewer suppliers who, in turn, will be expected to provide a wider range of services coupled with high quality and reduced overall costs. We believe that we are well positioned to benefit from increased OEM outsourcing and the consolidation of suppliers. Additionally, while we are seeing supplier rationalization packages for instrument sourcing, it has not yet translated into any significant volume but has created incremental pricing pressure in the market. Based on projected capital spending, sluggish supplier rationalization, and our

current order activity, we have recalibrated our expected instrument volume to account for the current trend and a continued deliberate Instrument set roll out by our customers on the large scale program new knee launches. With regard to the Symmetry Surgical segment, we plan to continue to expand coverage and product portfolio to serve our hospital and surgery center direct customers consistently with our strategic principles.

Our strategic plan is focused on four distinct but synergistic areas:

- Being the trusted, industry leading orthopedic OEM supplier positioned to gain share in long-term growth segment;
- Diversifying our revenue base with our strategic, growing hospital direct medical device distribution business;
- Utilizing resources to pursue growth opportunities and acquisitions in appropriate Medical Device OEM adjacencies and add to hospital solutions portfolio; and
- Developing a robust intellectual property portfolio with a dedicated R&D team to drive future growth through innovation.

Using this strategy, we are striving to provide the best possible customer experience by offering superior value; the highest-quality new technology; customized services; superior support; and the combination of our products and services into our Total Solutions® offering. Historically, our growth has been driven organically from our core businesses as well as acquisitions designed to augment select areas of our business with more products, services, and technology.

Third Quarter Results of Operations

Revenue. Revenue for the three months ended September 28, 2013 decreased \$2,926, or 2.9%, to \$98,003 from \$100,929 for the comparable 2012 period. Revenue for each of our segments and principal product categories in these periods was as follows:

| Sales by product | Three Months Ended | | Dollar Change | Percent Change |
|---------------------------------|-----------------------------------|--------------------|---------------|----------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | | |
| OEM Solutions Revenue | | | | |
| Instrument | \$27,200 | \$29,633 | \$(2,433) | (8.2)% |
| Implant | 26,108 | 25,632 | 476 | 1.9% |
| Cases | 16,959 | 14,209 | 2,750 | 19.4% |
| Other | 5,518 | 6,658 | (1,140) | (17.1)% |
| Total OEM Solutions Revenue | 75,785 | 76,132 | (347) | (0.5)% |
| Total Symmetry Surgical Revenue | 22,218 | 24,797 | (2,579) | (10.4)% |
| Total Revenue | \$98,003 | \$100,929 | \$(2,926) | (2.9)% |

The \$347 decrease in OEM Solutions revenue resulted from decreased demand in our instrument and other product lines partially offset by increased customer demand within our cases and implants product lines and favorable foreign currency exchange rate fluctuations of \$312. Overall, we experienced increased revenues of 4.1% from our five largest OEM customers which drove the increase in cases and implants revenue and the decrease in instruments revenue. OEM Solutions Instrument revenue decreased \$2,433 driven by continued lower customer launch demand. OEM Solutions Implant revenue increased \$476 due to an increase in customer consumption and impacted by favorable exchange fluctuation of \$170. Case revenue increased \$2,750 due primarily to higher capital spending related to increased customer launch volume and impacted by favorable currency exchange fluctuation of \$209. OEM

Solutions Other product revenue decreased \$1,140 compared to third quarter 2012 driven by operational output issues at the Corporation's Clamonta Ltd. subsidiary and was impacted by unfavorable foreign currency exchange rate fluctuations of \$70.

The \$2,579 decrease in Symmetry Surgical revenue in the third quarter 2013 as compared to 2012 was primarily the result of sales disruptions associated with transitions to distributorships in the rest of the world related to the integration of the Codman surgical instruments business. In the U.S., we believe the harmonizing of the sales force as well as the distribution of our new comprehensive catalog has helped to stabilize the business, as evidenced by a slight sequential and year over year decrease in

sales. We also believe that a flat trend in 2013 with regard to surgical procedures in both the U.S. and internationally adversely impacted potential growth in this segment.

Gross Profit. Gross profit for the three months ended September 28, 2013 decreased \$3,697, or 13.1%, to \$24,529 from \$28,226 for the comparable 2012 period. Gross margin as a percentage of revenue decreased 3.0%, to 25.0% for the third quarter 2013 from 28.0% for the comparable 2012 period.

| | Three Months Ended September 28, 2013 | | |
|-----------------------------------|--|----------------------|----|
| | Dollars | As a % of Revenue | |
| | (unaudited) | | |
| 2012 period reported gross profit | \$28,226 | 28.0 | % |
| Change in organic revenue and mix | (1,093) | (1.1 |)% |
| Foreign currency impact | 86 | 0.1 | % |
| Manufacturing costs and other | (2,690) | (2.0 |)% |
| 2013 period reported gross profit | \$24,529 | 25.0 | % |

Gross margin was driven by a lower percentage of revenue from the Corporation's higher margin Symmetry Surgical segment as compared to the same period last year, along with gross margin pressure in the OEM Solutions segment due to operational issues at the Clamonta Ltd. subsidiary, lower volume in the Instruments segment, and the fire at the Sheffield, U.K. manufacturing plant.

Research and Development Expenses. For the three months ended September 28, 2013, research and development expenses decreased \$172 or 13.3% to \$1,121 from \$1,293 in the comparable period in 2012, primarily due to lower project expense, and costs associated with maintaining patents.

Sales and Marketing Expenses. For the three months ended September 28, 2013, sales and marketing expenses increased \$409 or 6.7% to \$6,516 from \$6,107 in the comparable period in 2012, primarily due to Symmetry Surgical catalog expenses as the Corporation launched a global distribution of the recently updated and comprehensive catalog.

General and Administrative Expenses. For the three months ended September 28, 2013, general and administrative expenses increased \$520 or 4.8%, to \$11,250 from \$10,730 in the comparable period in 2012. Significant items which impacted general and administrative expenses included:

| | Three Months Ended September 28, 2013 | | |
|--|--|----------------------|---|
| | Dollars | As a % of Revenue | |
| | (unaudited) | | |
| 2012 period reported General & Administrative expenses | \$10,730 | 10.6 | % |
| Symmetry Surgical infrastructure additional costs | 480 | | |
| Employee compensation and benefit costs paid in cash | 861 | | |
| Change in amortization of intangible assets | (224) | | |
| Change in stock compensation | (446) | | |
| Medical device excise tax expense | 181 | | |
| Other | (332) | | |
| 2013 period reported General & Administrative expenses | 11,250 | 11.5 | % |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

During 2013, we incurred increased costs for salaries, technology and professional fees associated with increased infrastructure to support the Symmetry Surgical segment. Employee compensation and benefit costs paid in cash increased due to an increase for self-insurance medical claims incurred during 2013 under the Corporation's U.S. based medical plan. These increases were partially offset by a reduction in performance based stock compensation expense and a reduction in amortization expense.

Asset Impairment. During the third quarter of fiscal 2013, we recorded a pre-tax non-cash charge during the third quarter in the amount of \$51,646. This amount included \$31,837 related to the OEM Solutions segment and \$19,809 related to the Symmetry Surgical segment. The impairment in OEM Solutions is primarily driven by our reduced outlook on revenues and profitability related to instrument production for future customer expenditures related to product launches and instrument replenishment as well as operational issues at our Clamonta, Ltd. subsidiary, which services the Aerospace industry. The impairment in Symmetry Surgical is primarily driven by lower revenue due to the previously disclosed integration challenges related to the 2011 acquisition of the Codman surgical instruments business from which we have not recovered as quickly as previously expected.

Facility Closure and Severance Costs. Results of Operations include pre-tax charges of \$508 and \$(76) for the three months ended September 28, 2013 and September 29, 2012, respectively. As of September 28, 2013, severance accruals related to these cost reduction actions totaled \$592 and were included in other accrued liabilities in the consolidated balance sheets.

Operating Income (loss). On a consolidated basis, operating income (loss) decreased \$56,684, or 557.3% for the three months ended September 28, 2013 as compared to the 2012 period due to a decline in OEM Solutions operating income of \$35,102 and a decline in Symmetry Surgical operating income of \$22,588 partially offset by a decline in Unallocated loss of \$1,006. Operating income (loss) for each of our segments in these periods was as follows:

| | OEM Solutions | | Symmetry Surgical | | Unallocated | | Consolidated Total | |
|--|---------------|------------|-------------------|------------|-------------|------------|--------------------|------------|
| | As a % | | As a % | | As a % | | As a % | |
| | Dollars | of Revenue | Dollars | of Revenue | Dollars | of Revenue | Dollars | of Revenue |
| | (unaudited) | | | | | | | |
| 2012 period reported operating income (loss) | \$9,394 | 11.9 % | \$4,298 | 17.3 % | \$(3,520) | (3.4) % | \$10,172 | 10.1 % |
| Impact of gross profit and SG&A | (3,136) | (3.7) % | (2,324) | (8.5) % | 1,006 | 0.9 % | (4,454) | (4.3) % |
| Impact of asset impairment | (31,837) | (41.2) % | (19,809) | (89.1) % | — | — % | (51,646) | (52.7) % |
| Facility closure and severance | (129) | (0.2) % | (455) | (2.0) % | — | — % | (584) | (0.6) % |
| 2013 period reported operating income (loss) | \$(25,708) | (33.2) % | \$(18,290) | (82.3) % | \$(2,514) | (2.5) % | \$(46,512) | (47.5) % |

OEM Solutions operating income declined by \$35,102 and was (33.2)% of segment revenue in the 2013 period as compared to 11.9% in the prior year period primarily due to a \$31,837 asset impairment charge, as well as operational issues at the Clamonta Ltd. subsidiary and a fire at the Sheffield, U.K. manufacturing plant. Symmetry Surgical operating income decreased by \$22,588 and was (82.3)% of segment revenue in the 2013 period as compared to 17.3% in 2012 primarily due to a \$19,809 asset impairment charge as well as a reduction in revenue discussed above and increased sales and marketing expenses. The decrease in the Unallocated loss is primarily related to lower performance-based stock compensation expense partially offset by higher self-insured healthcare claims.

Other (Income) Expense. Interest expense for the three months ended September 28, 2013 decreased \$400, or 8.4%, to \$4,337 from \$4,737 for the comparable period in 2012. This decrease is most significantly attributable to the decrease in debt outstanding by \$42,797 as compared to third quarter 2012.

Derivatives valuation consists of foreign currency forward contracts which were used to mitigate the effect of changes in the foreign exchange rates on net income. As of September 28, 2013, we had settled all of our outstanding forward

swap contracts. We recorded a loss of \$5 for the three months ended September 28, 2013 as compared to a gain of \$116 for the comparable period in 2012, which is a result of fluctuation in the Euro versus the US Dollar.

Other income for the three months ended September 28, 2013 and September 29, 2012 represents foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

Income Tax Expense. Our effective tax rate was a benefit of 33.2% for the three months ended September 28, 2013 as compared to an expense of 33.9% for the three months ended September 29, 2012. Provision for income taxes decreased by \$19,082, or 993.3%, to \$(17,161) for the three months ended September 28, 2013 from \$1,921 for the comparable 2012 period primarily due to a \$57,344 decrease in pre-tax income. The rate differs from the U.S. Federal statutory rate primarily due to the impact of non-deductible goodwill impairment of \$6,581, which was partially offset by the reductions to uncertain tax benefits due to the expiration of the statute of limitations, which had a \$4,970.

Nine Months Results of Operations

Revenue. Revenue for the nine months ended September 28, 2013 decreased \$5,134, or 1.7%, to \$298,815 from \$303,949 for the comparable 2012 period. Revenue for each of our segments and principal product categories in these periods was as follows:

| Sales by product | Nine Months Ended | | Dollar Change | Percent Change |
|---------------------------------|-----------------------------------|--------------------|---------------|----------------|
| | September 28, 2013 (unaudited) | September 29, 2012 | | |
| OEM Solutions Revenue | | | | |
| Instrument | \$83,445 | \$85,197 | \$(1,752) | (2.1)% |
| Implant | 80,213 | 75,499 | 4,714 | 6.2 % |
| Cases | 50,432 | 44,569 | 5,863 | 13.2 % |
| Other | 18,006 | 19,913 | (1,907) | (9.6)% |
| Total OEM Solutions Revenue | 232,096 | 225,178 | 6,918 | 3.1 % |
| Total Symmetry Surgical Revenue | 66,719 | 78,771 | (12,052) | (15.3)% |
| Total Revenue | \$298,815 | \$303,949 | \$(5,134) | (1.7)% |

The \$6,918 increase in OEM Solutions revenue resulted from increased customer demand within our implants and cases product lines, partially offset by decreased demand in our instrument and other product lines. Overall, we experienced increased revenues of 6.7% from our five largest OEM customers. OEM Solutions Instrument revenue decreased \$1,752 due to a 3.2% decrease from our five largest OEM customers partially offset by higher demand from other medical customers. OEM Solutions Implant revenue increased \$4,714 driven by increased customer consumption demand as well as the timing of stocking orders and inventory adjustments at our customers. Case revenue increased \$5,863 due primarily to higher capital spending by our customers to support launch volumes as well as favorable foreign currency exchange rate fluctuations of \$307. OEM Solutions Other product revenue decreased \$1,907 driven by operational output issues at the Corporation's Clamonta Ltd. subsidiary as well as unfavorable foreign currency exchange rate fluctuations of \$269.

The \$12,052 decrease in Symmetry Surgical revenue in the nine months ended September 28, 2013 as compared to 2012 was primarily tied to a decline in sales of products which were acquired in a late 2011 acquisition from Johnson & Johnson ("J&J") and migrated from a transition services agreement with J&J in the third and fourth quarter of 2012. In the U.S. sales decreased \$6,752 as the need for customers to change their internal ordering procedures to order the acquired products from Symmetry Surgical instead of J&J impacted 2013 sales and may have led to increasing effective competition and lost market share. Outside the U.S. sales weakness of \$5,300 was due to the need to transition the business from J&J affiliates to Symmetry Surgical distributors. The transition required regulatory authorization transfers away from J&J and, along with local market effectiveness in many cases caused a decline in revenue.

Gross Profit. Gross profit for the nine months ended September 28, 2013 decreased \$3,897, or 4.9%, to \$76,244 from \$80,141 for the comparable 2012 period. Gross margin as a percentage of revenue decreased 0.9%, to 25.5% for the nine months ended September 28, 2013 from 26.4% for the comparable 2012 period.

| | Nine Months Ended September 28, 2013 | | |
|-----------------------------------|---|----------------------|----|
| | Dollars | As a % of Revenue | |
| | (unaudited) | | |
| 2012 period reported gross profit | \$80,141 | 26.4 | % |
| Change in organic revenue and mix | (3,635) | (1.2 |)% |
| Foreign currency impact | 60 | — | % |
| Manufacturing costs and other | (322) | 0.3 | % |
| 2013 period reported gross profit | \$76,244 | 25.5 | % |

Gross margin was driven by a lower percentage of revenue from the Corporation's higher margin Symmetry Surgical segment as compared to the same period last year, along with gross margin pressure in the OEM Solutions segment due to operational issues at the Clamonta Ltd. subsidiary, lower volume in the Instruments product line, and the fire at the Sheffield, U.K. manufacturing plant. These unfavorable factors were partially offset by the efficiencies resulting from the OEM Solutions increased revenue as well as lean initiatives.

Research and Development Expenses. For the nine months ended September 28, 2013, research and development expenses increased \$461 or 15.4% to \$3,459 from \$2,998 in the comparable period in 2012, primarily due to incremental projects, increased project expense and costs associated with maintaining patents.

Sales and Marketing Expenses. For the nine months ended September 28, 2013, sales and marketing expenses increased \$583 or 2.9% to \$20,451 from \$19,868 in the comparable period in 2012, primarily due to Symmetry Surgical catalog expenses as the Corporation launched a global distribution of the recently updated and comprehensive catalog.

General and Administrative Expenses. For the nine months ended September 28, 2013, general and administrative expenses increased \$2,823 or 8.7%, to \$35,154 from \$32,331 in the comparable period in 2012. Significant items which impacted general and administrative expenses included:

| | Nine Months Ended September 28, 2013 | | |
|--|---|----------------------|---|
| | Dollars | As a % of Revenue | |
| | (unaudited) | | |
| 2012 period reported General & Administrative expenses | \$32,331 | 10.6 | % |
| Symmetry Surgical infrastructure additional costs | 1,706 | | |
| Employee compensation and benefit costs paid in cash | 2,512 | | |
| Change in amortization of intangible assets | (694) | | |
| Medical device excise tax expense | 762 | | |
| Management transition expenses | (174) | | |
| Change in stock compensation | (1,142) | | |
| Other | (147) | | |
| 2013 period reported General & Administrative expenses | \$35,154 | 11.8 | % |

During 2013, we incurred increased costs for salaries, technology and professional fees associated with increased infrastructure to support the Symmetry Surgical segment. Employee compensation and benefit costs paid in cash increased due to an increase in self-insurance medical claims incurred during 2013 under the Corporation's U.S. based medical plan. The full year impact of the Medical Device Excise Tax is an increase of \$762. These increases were

partially offset by a reduction in performance-based stock compensation expense and a reduction in amortization expense.

Asset Impairment. During the third quarter of fiscal 2013, we recorded a pre-tax non-cash charge during the third quarter in the amount of \$51,646. This amount included \$31,837 related to the OEM Solutions segment and \$19,809 related to the Symmetry Surgical segment. The impairment in OEM Solutions is primarily driven by our reduced outlook on revenues and profitability related to instrument production for future customer expenditures related to product launches and instrument replenishment as well as operational issues at our Clamonta, Ltd. subsidiary, which services the Aerospace industry. The impairment in

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Symmetry Surgical is primarily driven by lower revenue due to the previously disclosed integration challenges related to the 2011 acquisition of Codman surgical instruments business which we have not recovered from as quickly as previously expected.

Facility Closure and Severance Costs. Results of Operations include pre-tax charges of \$1,431 and \$596 for the nine months ended September 28, 2013 and September 29, 2012, respectively. As of September 28, 2013, severance accruals related to these cost reduction actions totaled \$592 and were included in other accrued liabilities in the consolidated balance sheets.

Operating Income (loss). On a consolidated basis, operating income (loss) decreased \$60,245, or 247.4% for the nine months ended September 28, 2013 as compared to the 2012 period due to a decline in OEM Solutions operating income of \$29,696 and Symmetry Surgical operating income of \$31,415 offset by an reduced Unallocated loss of decrease \$866. Operating income (loss) for each of our segments in these periods was as follows:

| | OEM Solutions | | Symmetry Surgical | | Unallocated | | Consolidated Total | |
|--|---------------|-------------------|-------------------|-------------------|-------------|-------------------|--------------------|-------------------|
| | Dollars | As a % of Revenue | Dollars | As a % of Revenue | Dollars | As a % of Revenue | Dollars | As a % of Revenue |
| (unaudited) | | | | | | | | |
| 2012 period reported operating income (loss) | \$ 18,047 | 7.8 % | \$ 15,085 | 19.1 % | \$(8,784) | (2.8) % | \$ 24,348 | 8.0 % |
| Impact of gross profit and SG&A | 2,067 | 0.8 % | (11,080) | (13.1) % | 1,249 | 0.3 % | (7,764) | (2.4) % |
| Asset impairment | (31,837) | (13.5) % | (19,809) | (29.7) % | — | — % | (51,646) | (17.3) % |
| Facility closure and severance | 74 | — % | (526) | (0.8) % | (383) | (0.1) % | (835) | (0.3) % |
| 2013 period reported operating income (loss) | \$(11,649) | (4.9) % | \$(16,330) | (24.5) % | \$(7,918) | (2.6) % | \$(35,897) | (12.0) % |

OEM Solutions operating income declined by \$29,696 and was (4.9)% of segment revenue in the 2013 period as compared to 7.8% in the prior year period due to a \$31,837 asset impairment charge, partially offset by increases in revenue and gross margin and reduced impacts of facility closure and severance costs. Symmetry Surgical operating income decreased by \$31,415 and was (24.5)% of segment revenue in the 2013 period as compared to 19.1% in 2012 primarily due to a \$19,809 asset impairment charge as well as a reduction in revenue as discussed above and increased sales and marketing expenses. The decrease in the Unallocated operating costs is primarily related to lower performance based stock compensation expense partially offset by higher employee healthcare expenses.

Other (Income) Expense. Interest expense for the nine months ended September 28, 2013 decreased \$1,397, or 9.4%, to \$13,508 from \$14,905 for the comparable period in 2012. This decrease is most significantly attributable to the decrease in debt outstanding by \$42,797 as compared to third quarter 2012.

Derivatives valuation consists of foreign currency forward contracts which were used to mitigate the effect of changes in the foreign exchange rates on net income. As of September 28, 2013, we had settled all of our outstanding forward swap contracts. We recorded a loss of \$242 for the nine months ended September 28, 2013 as compared to a gain of \$179 for the comparable period in 2012, which is a result of fluctuation in the Euro versus the US Dollar.

Other income for the nine months ended September 28, 2013 and September 29, 2012 represents foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

Income Tax Expense. Our effective tax rate was a benefit of 33.5% for the nine months ended September 28, 2013 as compared to an expense of 39.1% for the nine months ended September 29, 2012. Provision for income taxes decreased by \$20,919, or 525.6%, to \$(16,939) for the nine months ended September 28, 2013 from \$3,980 for the comparable 2012 period primarily due to a \$60,764 decrease in pre-tax income. The rate differs from the U.S. Federal statutory rate primarily due to the impact of non-deductible goodwill impairment of \$6,581, which was partially offset by the reductions to uncertain tax benefits due to the expiration of the statute of limitations, which had a \$4,970.

Liquidity and Capital Resources

Liquidity

Our principal sources of liquidity in the nine months ended September 28, 2013 were cash generated from operations and borrowings under our Amended Credit Agreement. Principal uses of cash in the nine months ended September 28, 2013

included capital expenditures and debt service. We expect that our principal uses of cash in the future will be to finance working capital, to pay for capital expenditures, to service debt and to fund possible future acquisitions.

We believe our cash resources will permit us to stay committed to our strategic plan of increasing our share in the orthopedic market and expanding into other medical device segments and growing the business.

Operating Activities. Operating activities generated cash of \$34,389 in the nine months ended September 28, 2013 compared to \$51,960 for the nine months ended September 29, 2012, a decrease of \$17,571. The decrease in cash from operations is primarily a result of a reduction in working capital and net income. Net cash provided by working capital for the nine months ended September 28, 2013 was \$13,391 lower than the comparable 2012 period. Aggregate adjustments for non-cash items positively impacted operating cash flows by \$59,703, a \$35,665 increase from the comparable prior year period, primarily due to an asset impairment charge of \$51,646 offset by a decrease in our deferred income tax provision of \$17,029, fluctuations in foreign currency of \$1,564, unrealized derivative valuation gains of \$421 and a decrease in stock based compensation of \$1,142.

Investing Activities. Capital expenditures of \$7,786 were \$1,342 lower in the nine months ended September 28, 2013 compared to the nine months ended September 29, 2012.

Financing Activities. Financing activities used \$32,729 of cash in the nine months ended September 28, 2013 compared to usage of \$49,735 in the nine months ended September 29, 2012. This decrease in cash used by financing activities is due primarily to a \$43,717 increase in net borrowings on the revolving credit agreement and short term borrowings, partially offset by increases in net payments on bank term loans and capital lease obligations of \$25,838.

Capital Expenditures

Capital expenditures totaled \$7,786 for the nine months ended September 28, 2013, compared to \$9,128 for the nine months ended September 29, 2012. Expenditures were primarily for increased automation, replacement of existing equipment and investment in Symmetry Surgical infrastructure.

Debt and Credit Facilities

The Corporation's Amended Credit Agreement, which is senior and secured, currently provides for a \$200,000 revolving line of credit (Bank Revolver) and a \$50,000 bank term loan (Bank Term Loan). The Amended Credit Agreement also includes an accordion feature, which permits us to borrow up to an additional \$50,000 in the form of additional term loans or an increase in the Bank Revolver subject to the terms and conditions set forth in the Amended Credit Agreement. Borrowings under the Amended Credit Agreement bear interest at a rate per annum based upon LIBOR, the Federal Funds rate or the Lenders' prime rate, in each case plus an applicable margin, at the Corporation's option. The Bank Term Loan is to be repaid in quarterly installments of \$2,778, may be prepaid, in whole or in part, at the option of the Corporation, and is required to be prepaid using all or a portion of the net cash proceeds of certain asset sales, recovery events, and issuances of new debt or equity and, depending on the Corporation's Total Leverage Ratio (as defined in the Amended Credit Agreement), using a portion of the Corporation's Excess Cash Flow (as defined in the Amended Credit Agreement) (the "Excess Cash Flow Prepayment"). The Excess Cash Flow Prepayment is required to be made within 90 days of the end of the fiscal year in which the Excess Cash Flow is generated. The Bank Revolver matures on November 3, 2015 and the Bank Term Loan matures on December 31, 2016.

As of September 28, 2013, we had an aggregate of \$181,845 of outstanding indebtedness, which consisted of \$95,000 of borrowings on our Bank Revolver; \$18,288 of borrowings on a Bank Term Loan; \$67,008 of Term Notes; and \$1,549 of capital lease obligations. We had one outstanding letter of credit as of September 28, 2013, in the amount of

\$100.

The Amended Credit Agreement contains various financial covenants, including covenants imposing a maximum ratio of total debt to EBITDA (as defined in the Amended Credit Agreement) and prescribing a minimum ratio of EBITDA to fixed charges (as defined in the Amended Credit Agreement). The Amended Credit Agreement also contains covenants restricting certain corporate actions, including asset dispositions, acquisitions, payment of dividends and certain other restricted payments, changes of control, incurring indebtedness, incurring liens, making loans and investments and transactions with affiliates. The Amended Credit Agreement is secured by substantially all of the assets of the Corporation (and its U.S. subsidiaries) and also contains customary events of default.

The Corporation currently has \$67,008 of Term Notes outstanding that mature on December 29, 2017. The outstanding principal balance of the Term Notes bears interest at a rate of 14% per annum. The Term Notes include customary

26

representations, warranties and covenants made for the benefit of the parties to the agreement. The covenants include, but are not limited to, requirements to provide financial information and notice of other events to the lenders, as well as restrictions on the incurrence of indebtedness, the creation or existence of liens, sales of assets, transactions with affiliates and other matters. The Term Notes also include financial covenants, including covenants requirement a maximum ratio of total debt to EBITDA (as defined in the Term Notes Agreement) and ratio of minimum fixed charges to EBITDA. The agreement includes customary events of default, including but not limited to, failure to pay any principal, interest, fees or other amounts when due, default under any covenant or any agreement in any loan document (subject to cure periods in some cases), cross-default with other debt agreements and certain bankruptcy and insolvency events. While not secured by the Corporation's assets, repayment of amounts outstanding under the Term Notes is guaranteed by all of Symmetry's U.S. subsidiaries.

In May 2013, the Corporation was notified by one of its lenders that payments made by the Corporation in the first quarter of 2013 had been applied to the Bank Revolver, rather than the Bank Term Loan to satisfy the Corporation's obligation to make the Excess Cash Flow Prepayment as required by the Amended Credit Agreement. The failure to timely make the Excess Cash Flow Prepayment was a default under the Amended Credit Agreement and Term Notes. The Corporation entered into a limited waiver with its lenders under the Amended Credit Agreement and with the holders of the Term Notes that waived the event of default resulting from the failure to timely make the Excess Cash Flow Prepayment, and the Corporation made the required \$22,073 Excess Cash Flow Prepayment with borrowings under the Corporation's Bank Revolver. Future quarterly payments due on the Bank Term Loan will be reduced by a proportionate amount as a result of the reduction in outstanding principal from the Excess Cash Flow payment.

As of September 28, 2013, the most restrictive financial covenants per the Corporation's lending arrangements included the debt to EBITDA covenant ratio to be less than 3.50:1, and our ratio was approximately 3.20:1. The minimum interest coverage ratio requires us to be greater than 1.20:1, and our ratio at September 28, 2013 was approximately 1.84:1. As of December 28, 2013, these financial covenants become more restrictive and then remain in effect until maturity. The debt to EBITDA covenant ratio is required to be less than 3.25:1 and the minimum interest coverage ratio requires us to be greater than 1.25:1. Our ability to maintain compliance with the more restrictive financial covenants in place as of December 28, 2013 is dependent upon the Corporation meeting or exceeding its earnings forecasts, as well as significant reductions in debt levels from September 28, 2013. If we are unable to achieve earnings forecasts and also significantly reduce debt, we will be unable to comply with the more restrictive covenants. Our ability to achieve these actions will be affected by prevailing economic conditions and financial, business, regulatory and other factors, including some factors that are beyond our control. In an effort to replace higher interest rate mezzanine debt which is callable at the end of December 2013 with lower interest rate senior-secured debt and the potential difficulty in meeting our financial covenants at December 28, 2013, we have entered into negotiations with our lenders on our capital structure. Such discussions have included refinancing our existing debt which would include revising our required debt covenants. If we are unable to maintain compliance under our debt covenants or refinance our existing debt including revising our required debt covenants, we could ultimately go into default under the terms of our various debt agreements, which may result in acceleration of all obligations or obtaining a waiver.

We intend to closely monitor our compliance with all of our debt covenants. After obtaining the waivers discussed above, we were in compliance with all covenants as of September 28, 2013. We intend to closely monitor our revenues, cost of revenues and selling, general and administrative expenses to manage our ability to meet our debt covenant requirements.

We believe that cash flow from operating activities and borrowings on our Bank Revolver will be sufficient to fund currently anticipated working capital, planned capital spending and debt service requirements for the foreseeable future, including at least the next twelve months.

Off-Balance Sheet Arrangements

Our off-balance sheet arrangements include our operating leases and letters of credit, which are available under the Amended Credit Agreement. We had one letter of credit outstanding as of September 28, 2013 in the amount of \$100.

Environmental

Our facilities and operations are subject to extensive federal, state, local and foreign environmental and occupational health and safety laws and regulations. These laws and regulations govern, among other things, air emissions; wastewater discharges; the generation, storage, handling, use and transportation of hazardous materials; the handling and disposal of hazardous wastes; the cleanup of contamination; and the health and safety of our employees. Under such laws and regulations, we are required to obtain permits from governmental authorities for some of our operations. If we violate or fail to comply with these laws, regulations or permits, we could be fined or otherwise sanctioned by regulators. We could also be held responsible for costs and damages arising from any contamination at our past or present facilities or at third-party waste disposal sites. We cannot

completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur material liability as a result of any contamination or injury.

We incurred minimal capital expenditures for environmental, health and safety in the nine months ended September 28, 2013 and September 29, 2012.

In connection with past acquisitions, we completed Phase I environmental assessments and did not find any significant issues that we believe needed to be remediated. We updated those Phase I assessments in conjunction with providing security for financing for the Codman acquisition and found no issues at that time either. Based on information currently available, we do not believe that we have any material environmental liabilities. We cannot be certain, however, that environmental issues will not be discovered or arise in the future related to these acquisitions.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. Our Annual Report on Form 10-K for fiscal year ended December 29, 2012, includes a summary of the critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no material changes to these critical accounting policies that impacted our reported amounts of assets, liabilities, revenues or expenses during the nine months ended September 28, 2013.

Impairment of Long-Lived Assets, Including Intangible Assets. We assess the impairment of definite lived long-lived assets when circumstances indicate the carrying value of an asset may not be recoverable based on the undiscounted future cash flows of an asset. If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded. Fair values are determined based on quoted market values, undiscounted cash flows, or external appraisals, as applicable. We review long-lived assets for impairment at the individual asset or the asset group level for which the lowest level of independent cash flows can be identified. Intangible assets subject to amortization consist of technology and non-compete intangible assets which are amortized using the straight-line method, as well as customer related intangible assets which are amortized on an accelerated method. All of the Corporation's intangible assets were acquired in connection with our various acquisitions. The Corporation is required to reassess the expected useful lives of existing intangible assets annually. We reviewed our amortizing intangible assets and did not record any impairment related to these assets in fiscal 2012. However, impairment charges were recorded at one of our reporting units in 2013 related to customer relationships and tradenames of \$1,403 and \$921, respectively.

We test goodwill for impairment annually on the first day of the fourth fiscal quarter and more frequently if circumstances warrant. We determine fair values for each of the reporting units using an income approach. When available and appropriate, we use comparative market multiples to corroborate discounted cash flow results. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. We use our internal forecasts to estimate future cash flows and include an estimate of long-term future growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ from those assumed in our forecasts. We derive our discount rates using a capital asset pricing model and analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. Discount rates used in our reporting unit valuations ranged from 12.5% to 15.8%. Valuations using the market approach reflect prices and other relevant observable information generated by market transactions involving comparable businesses. Compared to the market approach, the income approach more closely aligns each reporting unit valuation to our business profile, including geographic markets served and product offerings. Required rates of return, along with uncertainty inherent in the forecasts of

future cash flows, are reflected in the selection of the discount rate.

We conducted our annual impairment test for our various reporting units, and recorded a preliminary impairment charge of \$51,646 related to three of our reporting units in 2013. The fair value of two of our reporting units that were not impaired and that contained total goodwill of \$118,918 exceeded carrying value by 3% and 5%, respectively, as of September 28, 2013. An impairment charge was recorded in 2013 related to one reporting unit which did not result in the full impairment of goodwill. Subsequent to the impairment, goodwill on this one reporting unit of \$62,955 was recorded on the condensed consolidated balance sheet as of September 28, 2013. Revenue growth rates assumed for these reporting units were approximately 1-7% in 2014 and beyond. These growth rates are driven by new product launches as well as further integration of acquisitions and recapturing market share. A significant decline in our revenue and earnings or a significant decline in the price of common stock could result in an impairment charge in the future.

Intangible assets with an indefinite life are not amortized but are subject to review each reporting period to determine whether events and circumstances continue to support an indefinite useful life as well as an annual impairment test. In connection with our annual impairment test, we recognized an impairment charge of \$921 and \$610 related to tradenames and in-process research and development, respectively, as the carrying values of these assets exceeded the associated cash flows. We reviewed all other intangible assets and have not recorded any impairment related to the remaining assets for the nine months ended September 28, 2013 or fiscal 2012.

The assessment of the recoverability of long-lived assets reflects management's assumptions and estimates. Factors that management must estimate when performing impairment tests include sales volume, prices, inflation, discount rates, exchange rates, tax rates and capital spending. Significant management judgment is involved in estimating these factors, and they include inherent uncertainties. Measurement of the recoverability of these assets is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific reporting unit to which the assets are attributed. Changes in these estimates could change our conclusion regarding the impairment of goodwill or other intangible assets and potentially result in a non-cash impairment in the future period

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For financial market risks related to changes in interest rates, foreign currency exchange rates, commodity prices and the effects of inflation, reference is made to Item 7a "Quantitative and Qualitative Disclosures About Market Risk" contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 29, 2012. Our exposure to these risks, at the end of the third quarter covered by this report, has not changed materially since December 29, 2012.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the "Exchange Act"). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the fiscal quarter covered by this report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 28, 2013.

(b) Changes in Internal Control over Financial Reporting

There have been no changes in our "internal control over financial reporting" (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The Corporation has completed the integration of its multiple Symmetry Surgical operations, as well as its Manchester, New Hampshire and Lansing, Michigan operations into its existing Enterprise Resource Planning (ERP) platform. An ERP system is a fully-integrated set of programs and databases that incorporate order processing, planning and scheduling, purchasing, accounts receivable and inventory management and accounting. In connection with these ERP consolidations, the Corporation has updated its internal controls over financial reporting, as necessary, to accommodate modifications to its business processes and accounting procedures. The Corporation does not believe that this ERP system consolidation had an adverse effect on the Corporation's internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012, which could materially affect our business, financial condition or future results. There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following information is provided pursuant to Item 703 of Regulation S-K:

Issuer Purchases of Equity Securities

| Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (Or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|-----------|---|--|---|---|
| July 2013 | 5,925 | \$8.38 | — | — |

(1) The shares repurchased represent shares of our common stock that employees elected to surrender to the Corporation to satisfy their tax withholding obligations upon the vesting of shares of restricted stock. We do not consider this a share buyback program.

ITEM 6. EXHIBITS

| | |
|---------|--|
| 31.1 | Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 31.2 | Certification of Chief Financial Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| 101.INS | XBRL Instance Document~ |
| 101.SCH | XBRL Taxonomy Extension Schema Document~ |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document~ |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document~ |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document~ |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document~ |

* Filed concurrently herewith.

~ In accordance with Rule 406T under Regulation S-T, the XBRL-related information in Exhibit 101 shall be deemed “furnished” and not “filed.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYMMETRY MEDICAL INC.

By /s/ Thomas J. Sullivan
Thomas J. Sullivan,
President and Chief Executive Officer
(Principal Executive Officer)

By /s/ Fred L. Hite
Fred L. Hite,
Senior Vice President and Chief Financial
Officer
(Principal Financial Officer)

November 7, 2013